more emphasis on promoting adherence with Pradaxa (dabigatran), Xarelto (rivaroxaban), and Eliquis (apixaban) blood thinners

You'll see more emphasis on promoting adherence with Pradaxa (dabigatran), Xarelto (rivaroxaban), and Eliquis (apixaban) blood thinners...due to a new boxed warning.

FDA requires these special boxed warnings in the package insert to call attention to significant problems.

The concern is that stopping one of these "anticoagulant" blood thinners...even for a few days...can quickly return patients to their risk of stroke before starting therapy.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote